These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 18351154

  • 1. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
    Grazio S, Morović-Vergles J.
    Reumatizam; 2007; 54(2):89-92. PubMed ID: 18351154
    [Abstract] [Full Text] [Related]

  • 2. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
    Anić B, Grazio S.
    Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
    [Abstract] [Full Text] [Related]

  • 3. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 4. [Drug therapy for prevention of falls and fractures].
    Ringe JD.
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F, Borges JL, Curiel MD.
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 9. [FOSAVANCE -- alendronate plus vitamin D in a weekly tablet].
    Praxis (Bern 1994); 2006 Jul 05; 95(27-28):2 p following 1084. PubMed ID: 16888927
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
    Keen R, Jodar E, Iolascon G, Kruse HP, Varbanov A, Mann B, Gold DT.
    Curr Med Res Opin; 2006 Dec 05; 22(12):2375-81. PubMed ID: 17257451
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Non-hormonal treatments of postmenopausal osteoporosis].
    Malaise O, Neuprez A, Reginster JY.
    Gynecol Obstet Fertil; 2008 Dec 05; 36(7-8):815-22. PubMed ID: 18653373
    [Abstract] [Full Text] [Related]

  • 16. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
    Bartl R, Götte S, Hadji P, Hammerschmidt T.
    Dtsch Med Wochenschr; 2006 Jun 02; 131(22):1257-62. PubMed ID: 16755420
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY.
    J Bone Joint Surg Am; 2008 Oct 02; 90(10):2142-8. PubMed ID: 18829912
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 02; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.